Clinical Trials Logo

Malignant Brain Stem Tumor clinical trials

View clinical trials related to Malignant Brain Stem Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04668508 Recruiting - Glioma Clinical Trials

Anlotinib to Malignant Brainstem Glioma

Start date: November 24, 2020
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma. Twenty five patients will be enrolled in the study who is diagonsis with malignant brainstem glioma. The primary objective includes disease control rate (DCR), the role of antinib combined with radiotherapy in improving quality of life and 6-month progression-free survival rate. The secondary objective include overall survival (OS), toxicity profile. Exploratory objectives include the use of plasma specimens and cerebrospinal fluid (if possible) to detect biomarkers predicting the efficacy of anlotinib.